Todd Thompson, PhD
Associate Professor: Pharmaceutical Sciences
Office Location: RIB 295
Phone: (505) 925-4710
Thompson received a BS in pharmacy from the University of New Mexico in 1987 and a PhD in molecular and environmental toxicology from the University of Wisconsin – Madison in 1997.
Thompson’s scientific expertise is in cellular and molecular carcinogenesis. His research is directed toward precision medicine-based considerations for cancer prevention and treatment and he has four issued patents for methods to treat prostate cancer and melanoma. The Thompson laboratory studies molecular pathways in prostate cancer development using human prostate cancer cells in culture and xenograft and transgenic mouse models of prostate cancer. A combination of molecular genetic and biochemical techniques are used to examine androgen-driven pathways and androgen-independent pathways as targets for prostate cancer prevention and treatment. His publications encompass research on endocrine-sensitive cancers, including breast and prostate cancer. The Thompson laboratory developed the Multifunctional Androgen Receptor Screening (MARS) assay, which can rapidly detect both androgen receptor agonists and antagonists.
Practice and Research Pages
- Society of Toxicology
- Mountain West Society of Toxicology
- American Association of Pharmaceutical Scientists
- American Association of Colleges of Pharmacy
- American Association for Cancer Research
UNM Center for Molecular Discovery to market technologies through Accelera Diagnostics, UNM.STC option agreement
(HSCNewsBeat; July 16, 2014) ─ Accelera Diagnostics and STC.UNM recently announced a limited exclusive option agreement for a portfolio of technologies developed at UNM’s Center for Molecular Discovery (CMD), including compounds, repurposed drugs, devices and highly sophisticated methods for analysis and characterization used for the discovery of new treatments for cancer and other diseases.
(HSCNewsBeat; January 3, 2012) ─ A synthetic version of a compound found in turmeric, called curcumin, has shown success in slowing and even stopping the growth of prostate cancer cells in the laboratory. This synthetic compound, dubbed ca27, harnesses the anti-cancer potential of curcumin in such a way that it is effective in the body, unlike natural curcumin, which is not readily absorbed.